During #HFSA2024 today, we presented new positive findings from our Phase 2a trial of our experimental therapy, which is being studied as a potential disease-modifying treatment for #HFpEF. Learn more: bit.ly/3XOkBdG

Last week, our CEO Dr. Jayson Dallas shared how Rivus is aiming to "be the best in #cardiometabolic disease" to stand out amid the crowded landscape during a panel at #BIF24. Thank you @IamBiotech for hosting this insightful discussion!

We’re sharing a corporate update at #JPM25 highlighting our clinical development progress for our lead investigational therapy and our full pipeline of innovative Controlled Metabolic Accelerators. Read more: bit.ly/3PrVv0g

Thank you David Geffen School of Medicine at UCLA for hosting our CMO Dr. Rob Schott to discuss how our innovative approach supports body fat loss while preserving muscle. Learn more about our research: bit.ly/48RjmPS

This #HeartMonth we're reinforcing our commitment to patients w/ #HeartFailure w/ preserved ejection fraction, a debilitating disease that severely impacts exercise capacity & quality of life. Discover our potentially disease-modifying treatment for #HFpEF bit.ly/4hQV2B0

Last week, our team met to celebrate our progress in advancing our new class of investigational medicines for obesity and its continuum of cardiometabolic diseases and to plan for an exciting year ahead.

Inflammation due to visceral fat is a key driver of #HeartFailure w/ preserved ejection fraction. Our approach to treating cardiometabolic diseases driven by obesity like #HFpEF aims to reduce body fat while preserving muscle. Explore more: bit.ly/4hQV2B0 #HeartMonth

On #WOD2025, we join the growing community of experts in highlighting the need to refocus the #obesity & weight management conversation to better reflect the importance of fat-specific weight loss & muscle preservation. Learn about our innovative approach: bit.ly/4hQV2B0

Our Ph2a HuMAIN trial showing fat-specific weight loss while preserving muscle mass in patients with obesity-related #HFpEF is now published in JAMA Cardiology. Read more about the study findings: bit.ly/4bOfrET

Six years ago, we embarked on a mission to develop next-generation therapies for obesity. We're proud of our progress in advancing our innovative CMAs with 400+ patients treated to date in our clinical trials. Learn more: bit.ly/4hQV2B0

We're excited to welcome David Grainger & Meg Fitzgerald to our leadership team and to draw on their deep expertise as we advance our innovative pipeline of CMAs. Learn more about our growth, including our new office in South San Francisco: bit.ly/3FXMfiX

Liver diseases like #MASH & #MASLD are on the rise & are especially prevalent in people w/ obesity. Ahead of #WorldLiverDay we highlight the importance of liver health & the vital role fat-specific weight loss can play in improving liver function. See more bit.ly/4hQV2B0

Metabolic dysfunction-associated steatohepatitis (#MASH) is a serious liver condition involving fat accumulation and inflammation. At Rivus, we are committed to raising awareness and advancing treatment options for MASH: bit.ly/4hQV2B0

Our Chief Scientific Officer, Shaharyar Khan, spoke with Xtalks Webinars about the innovative science behind our controlled metabolic accelerators and what's ahead for our pipeline. Watch the full podcast here: bit.ly/3ED9QoW

Our controlled metabolic accelerators are paving the way for fat-specific weight loss while preserving muscle mass by leveraging mitochondrial biology. Learn more about the science behind our innovations by reading the full article in Endpoints News: bit.ly/4jRVsIm

Did you know that obesity, type 2 diabetes, and high cholesterol are risk factors for #MASH? Managing weight and a healthy diet can reduce risks and boost liver health. Learn more about our innovative approach to treating MASH through weight management: bit.ly/3GCRqVS

Muscle preservation is crucial in weight management, and often overlooked in traditional obesity treatments. At Rivus, we're prioritizing fat-specific weight loss treatments to improve health outcomes, especially in cardiometabolic diseases. Learn more: bit.ly/3GCRqVS

During #MensHealthMonth, we're highlighting the significant impact of obesity on men's health, particularly its impact on cardiometabolic diseases. Rivus is committed to supporting healthier lifestyles and empowering men to take control of their health! bit.ly/3GCRqVS

Today, we announced positive topline results from our Phase 2 trial evaluating our first-in-class Controlled Metabolic Accelerator in patients with metabolic dysfunction-associated steatohepatitis (#MASH). Read more in our press release: bit.ly/43VJKHA

"It's the patient experience that is the primary motivator for what we're working on." Our Chief Scientific Officer, Shaharyar Khan, sat down with Xtalks Webinars to discuss the innovative science behind our Controlled Metabolic Accelerators. Listen to their discussion: